This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Assistance Publique-Hopitaux De Paris, Biomedical Research Foundation of the Academy of Athens, Commissariat a L'energie Atomique Et Aux Energies Alternatives. Active years: 2022-2025.
Company Filing History:
1 out of 331 
1 out of 4 
1 out of 8,816 
Years Active: 2022-2025
Title: Aurelie Kamoun: Innovator in Cancer Diagnosis
Introduction
Aurelie Kamoun is a prominent inventor based in Paris, France. She has made significant contributions to the field of cancer diagnosis through her innovative research and development of biomarker proteins.
Latest Patents
Aurelie Kamoun holds a patent for her invention related to bladder cancer biomarker proteins. This invention encompasses a collection of signature peptides representing at least 10 proteins that are utilized for cancer diagnosis and prognosis. It includes an artificial protein comprising these signature peptides and a nucleic acid construct encoding for such an artificial protein. Furthermore, her invention outlines a method for cancer diagnosis and prognosis that involves analyzing at least 10 proteins in a urine sample from a subject. Additionally, it features an immunoassay product that comprises antibodies for detecting these proteins.
Career Highlights
Throughout her career, Aurelie Kamoun has worked with notable organizations, including Polyquant GmbH and Commissariat à l'Énergie Atomique et aux Énergies Alternatives. Her work has been instrumental in advancing the understanding and diagnosis of bladder cancer.
Collaborations
Aurelie has collaborated with esteemed colleagues such as Jerome Garin and Christophe Masselon, contributing to the collective knowledge and innovation in her field.
Conclusion
Aurelie Kamoun's work in developing biomarker proteins for cancer diagnosis exemplifies her commitment to advancing medical science. Her innovative contributions continue to impact the field of oncology significantly.